Phase II study of bendamustine, rituximab and cytarabine for patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma
Latest Information Update: 29 Jul 2021
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary) ; Filgrastim
- Indications Follicular lymphoma; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms GHSG-BRAC
- 26 Jul 2021 Status changed from recruiting to discontinued.
- 26 Jul 2021 Planned End Date changed from 1 Oct 2022 to 20 Mar 2021.
- 25 Jan 2013 New trial record